Literature DB >> 8888719

Omeprazole produces parietal cell hypertrophy and hyperplasia in humans.

D K Driman1, C Wright, G Tougas, R H Riddell.   

Abstract

While there is evidence that omeprazole may induce changes in parietal cells, the effect of acid suppression on parietal cells in humans is poorly documented. This study was undertaken to evaluate the effects of omeprazole in human parietal cells over time. The light microscopic morphology of parietal cells in gastric biopsies from 17 patients on omeprazole were compared with those from 13 patients on ranitidine and 20 patients on no acid-lowering medication. Light microscopic and ultrastructural morphology of parietal cells was also evaluated in an additional 14 patients before and after omeprazole administration. Objective measurements of parietal cell height, mass and number were analyzed using analyses of variance. Electron microscopy was used to evaluate parietal cell enlargement. Twenty-five of 31 biopsies from patients on omeprazole, 1 of 13 from patients on ranitidine, and 0 of 20 from patients on neither drug showed parietal cell enlargement. Parietal cell height, mass, and number were increased in omeprazole-treated patients compared with ranitidine-treated patients and those on neither drug, and with the group also evaluated prior to beginning omeprazole treatment. Parietal cell height and mass were increased in patients on omeprazole longer than 12 months compared with biopsies from patients on the drug for less than 12 months. Resin-embedded sections and electron microscopy showed enlarged parietal cells with prominence of cytoplasmic tubulovesicles with sparse secretory canaliculi. Parietal cell hypertrophy and hyperplasia develops in patients on chronic omeprazole therapy; this can be recognized on routine examination of histologic sections. These morphologic changes increase with duration of therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8888719     DOI: 10.1007/bf02093608

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Ultrastructural changes in oxyntic cells associated with secretory function: a membrane-recycling hypothesis.

Authors:  T M Forte; T E Machen; J G Forte
Journal:  Gastroenterology       Date:  1977-10       Impact factor: 22.682

Review 2.  The gastric H+,K+-ATPase: the site of action of omeprazole.

Authors:  G Sachs; B Wallmark
Journal:  Scand J Gastroenterol Suppl       Date:  1989

Review 3.  Acid pump blockers: what are their current therapeutic roles?

Authors:  M J Arens; J Dent
Journal:  Baillieres Clin Gastroenterol       Date:  1993-03

4.  The effect of omeprazole on ultrastructural changes in gastric parietal cells.

Authors:  H Karasawa; N Tani; T Miwa
Journal:  Gastroenterol Jpn       Date:  1988-02

5.  Structure and function of rat parietal cells during treatment with omeprazole, SCH 28080, SCH 32651, or ranitidine.

Authors:  H F Helander; H Mattsson; G Elm; S Ottosson
Journal:  Scand J Gastroenterol       Date:  1990-08       Impact factor: 2.423

6.  Effect of 7 years' daily oral administration of omeprazole to beagle dogs.

Authors:  C Säfholm; N Havu; H Forssell; G Sundell; H Mattsson
Journal:  Digestion       Date:  1994       Impact factor: 3.216

7.  Pharmacology and toxicology of omeprazole--with special reference to the effects on the gastric mucosa.

Authors:  E Carlsson; H Larsson; H Mattsson; B Ryberg; G Sundell
Journal:  Scand J Gastroenterol Suppl       Date:  1986

8.  Function and structure of parietal cells after H+-K+-ATPase blockade.

Authors:  J Fryklund; H F Helander; B Elander; B Wallmark
Journal:  Am J Physiol       Date:  1988-03

9.  Comparison of the effect of omeprazole--a substituted benzimidazole--and ranitidine--a potent H2-receptor antagonist--on histamine-induced gastric acid secretion and the ultrastructure of canine parietal cells.

Authors:  J Stachura; S J Konturek; M Cieszkowsky; W Dabroś; J Zakrzewska; J Konturek
Journal:  Hepatogastroenterology       Date:  1983-10

10.  Ultrastructure of inhibited parietal cells in the rat.

Authors:  H F Helander; G W Sundell
Journal:  Gastroenterology       Date:  1984-11       Impact factor: 22.682

View more
  15 in total

1.  A report of gastric fundic gland polyps.

Authors:  Adam Spiegel; Peter Stein; Mehul Patel; Roshan Patel; Edward Lebovics
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

2.  The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat.

Authors:  T D Barrett; G Lagaud; P Wagaman; J M Freedman; W Yan; L Andries; M C Rizzolio; M F Morton; N P Shankley
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

3.  Management of a Portal Hypertensive Polyp: Case Report of a Rare Entity.

Authors:  Waseem M Seleem; Amr Shaaban Hanafy
Journal:  Gastrointest Tumors       Date:  2019-09-04

4.  A matched case-control study of a novel Acid-pump antagonist and proton-pump inhibitor for the treatment of iatrogenic ulcers caused by endoscopic submucosal dissection.

Authors:  Yong Gil Kim; Byung-Ik Jang; Tae Nyeun Kim
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

Review 5.  Adverse effects of long-term proton pump inhibitor therapy.

Authors:  Edward Sheen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

6.  OsmoPrep-associated Gastritis: A Histopathologic Mimic of Iron Pill Gastritis and Mucosal Calcinosis.

Authors:  Karen Matsukuma; Dorina Gui; Kristin A Olson; Sooraj Tejaswi; Erica F Clayton; Anne Thai
Journal:  Am J Surg Pathol       Date:  2016-11       Impact factor: 6.394

7.  Treatment of Helicobacter pylori in Pediatrics.

Authors:  Samra S. Blanchard; Lara Bauman; Steven J. Czinn
Journal:  Curr Treat Options Gastroenterol       Date:  2004-10

Review 8.  The use of proton pump inhibitors in children: a comprehensive review.

Authors:  Troy E Gibbons; Benjamin D Gold
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 9.  Acid suppression and gastric atrophy: sifting fact from fiction.

Authors:  R M Genta
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

10.  Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours.

Authors:  C M Korse; M Muller; B G Taal
Journal:  Br J Cancer       Date:  2011-10-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.